Paper Details
- Home
- Paper Details
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Author: BriaEmilio, CannellaAntonella, D'ArgentoEttore, DamianoPaola, Di NoiaVincenzo, FerraraMiriam Grazia, MilellaMichele, PilottoSara, RibelliMarta, TortoraGiampaolo, VitaEmanuele
Original Abstract of the Article :
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deeper understanding of tumor molecular...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281569/
データ提供：米国国立医学図書館（NLM）
A New Era in Lung Cancer Treatment: Targeting Oncogene Addiction
This review delves into the advancements in non-small cell lung cancer (NSCLC) treatment, focusing on the concept of oncogene addiction and the development of targeted therapies. The review highlights the impact of tyrosine kinase inhibitors (TKIs) in revolutionizing NSCLC treatment, particularly for patients with specific driver mutations. The research underscores the importance of personalized medicine, tailoring treatment strategies based on the unique molecular characteristics of the tumor. The review discusses various driver mutations and the development of specific TKIs that effectively target these mutations, leading to improved outcomes for patients with oncogene-addicted NSCLC. The review also acknowledges the challenges of acquired resistance and the need for ongoing research to develop new therapies.
A Targeted Approach: Revolutionizing Lung Cancer Treatment
This review highlights the transformative impact of targeted therapies in treating NSCLC, particularly for patients with oncogene-addicted tumors. The research underscores the importance of personalized medicine, tailoring treatment strategies based on the unique molecular characteristics of the tumor. The review's findings encourage further research to develop new and innovative therapies for overcoming acquired resistance and improving long-term outcomes for patients with NSCLC.
Living Well with Lung Cancer: Embracing Personalized Medicine
This review encourages individuals with NSCLC to seek comprehensive testing and personalized treatment strategies based on their specific tumor characteristics. The research underscores the importance of early diagnosis and targeted therapy in improving outcomes for patients with oncogene-addicted NSCLC. The review emphasizes the need for continued research to develop new therapies and overcome acquired resistance, offering hope for a brighter future for patients with NSCLC. As a wise camel, I always say, 'Knowledge is power!'.
Dr.Camel's Conclusion
This review provides a comprehensive overview of the current state of targeted therapy in oncogene-addicted NSCLC. It highlights the transformative impact of TKIs in improving outcomes for patients with specific driver mutations and underscores the importance of personalized medicine in tailoring treatment strategies. The review encourages further research to develop new and innovative therapies for overcoming acquired resistance and improving long-term outcomes for patients with NSCLC.
Date :
- Date Completed n.d.
- Date Revised 2020-09-28
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.